Fortrea strengthens its early-stage clinical development footprint by integrating Worldwide Clinical Trials' specialized services, enhancing its bioanalytical platform and research capacity.
Fortrea has strategically expanded its early clinical development capabilities through the acquisition of Worldwide Clinical Trials' Early Phase Services business. This integration enhances the company's bioanalytical expertise and increases the overall capacity of its clinical research units, providing a more robust and integrated platform for its clients.
The acquisition expands Fortrea's early clinical development network, specifically adding specialized bioanalytical competencies and increased clinical research unit capacity.
It allows Fortrea to provide a more integrated platform for its clients, streamlining the early clinical development process.
Fortrea Holdings Inc. has finalized the acquisition of Worldwide Clinical Trials' Early Phase Services business. This strategic move bolsters the company's bioanalytical capabilities and expands its clinical research unit capacity to provide a more integrated platform for global clients.
The acquisition aims to expand Fortrea's early clinical development network, specifically enhancing bioanalytical capabilities and increasing clinical research unit capacity.